A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis-Reference-Cited by-同舟云学术

A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis

Published:2023-05-22 Issue:3 Volume:30 Page:290-296
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Ravichandran Sriram¹,Hall Andrew²,Jenner Matthew³,Garg Mamta⁴,Kishore Bhuvan⁵,Lachmann Helen¹,Gillmore Julian¹^ORCID,Pitchford Alexandra²,Oughton Jamie B.²,Mahmood Shameem¹,Sachchithantham Sajitha¹,Hawkins Philip¹,Brown Sarah²,Wechalekar Ashutosh¹

Affiliation:

1. National Amyloidosis Centre, Royal Free Campus, University College London, London, UK

2. Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK

3. Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, The UK

4. Leicester Royal Infirmary, Leicester, UK

5. Haematology Department, Heart of England NHS Trust, Birmingham, UK

Funder

Amgen, conducted an independent review of the study protocol but were not involved in the design, conduct, analysis or interpretation and provided study drug free of charge

Publisher

Informa UK Limited

Subject

Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2023.2169124

Reference22 articles.

1. Epidemiologic and Survival Trends in Amyloidosis, 1987–2019

2. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

3. Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

4. In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

5. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime;British Journal of Haematology;2024-06-05

2. AL amyloidosis: an overview on diagnosis, staging system, and treatment;Frontiers in Hematology;2024-05-08

3. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment;American Journal of Hematology;2023-12-14

4. Development of a hybrid artificial neural network method for evaluation of the sustainable construction projects;Acta logistica;2023-09-30